China-based diagnostic company, Shuwen Biotech, has signed a partnership agreement with Bliss Biopharmaceutical, a biopharmaceutical company specializing in the discovery, development, and commercialization of biotherapeutics for unmet medical needs.
Under the agreement, Shuwen will develop companion diagnostics for Bliss’ oncology drug candidates. Shuwen will also provide testing services in its CAP-certified central labs for BlissBio’s’ clinical trials. Beyond that, the terms of the collaboration remain undisclosed at this time.
Jay Z. Zhang, Shuwen’s chairman and CEO says, “This collaboration will fuel continued innovation by BlissBio and further demonstrate how Shuwen can deliver value through its strong companion diagnostics development team and its CAP-accredited lab facilities.” Zhang also suggests that BlissBio is not the only pharmaceutical company they have partnered with.
(Source: B3C Newswire)